Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1178P (RNA, U6 small nuclear 1178, pseudogene) is a predicted non-coding RNA pseudogene derived from the U6 small nuclear RNA (snRNA) gene family[2]. U6 snRNA is an essential component of the spliceosome, where it participates in pre-mRNA splicing[1][3]. However, RNU6-1178P specifically refers to a "pseudogene": a genomic sequence similar to the original U6 snRNA gene but lacking known transcriptional activity or established function[2][5]. Pseudogenes are common in the U6 family, resulting from genomic duplication or retrotransposition[1][5]. There is no evidence that RNU6-1178P is transcribed, processed, or plays a biological role, nor is it recognized as a therapeutic or diagnostic target. Its identification and naming primarily serve genomic cataloging rather than therapeutic utility[2][5].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1178, pseudogene (RNU6-1178P).